PRODUCT OVERVIEW

Faricimab-svoa (Vabysmo) is a modern intravitreal injection used to treat several serious retinal diseases that cause vision loss. It works inside the eye to reduce abnormal blood vessel leakage and swelling at the macula, which is the area responsible for sharp central vision. As a result, many patients experience vision stabilization and, in many cases, measurable visual improvement.

This treatment uses a dual-action design. It blocks both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2). Because of this combined mechanism, it targets two major pathways that drive retinal fluid buildup and vessel instability.

INDICATIONS

Doctors recommend Faricimab-svoa (Vabysmo) for properly evaluated patients with retinal vascular disease. These include:

1. Neovascular or “wet” age-related macular degeneration
2. Diabetic macular edema
3. Macular edema following retinal vein occlusion, in selected cases

Your retina specialist confirms eligibility through a dilated retinal exam and imaging tests such as OCT and retinal photography.

HOW THE TREATMENT WORKS

Abnormal retinal vessels often leak fluid and blood. Consequently, the macula becomes thick and swollen, and vision turns blurred or distorted. Faricimab-svoa binds VEGF and Ang-2, so it reduces leakage and improves vessel stability. Therefore, retinal swelling decreases and vision can recover or stabilize.

In many treatment plans, injections start monthly. Afterwards, your doctor may extend the interval depending on your response and imaging results.

PROCEDURE SUMMARY

The injection takes place in a sterile clinic setting. First, the eye is numbed with anesthetic drops. Next, the surface is cleaned to reduce infection risk. Then the medication is injected into the vitreous cavity using a very fine needle. The procedure usually lasts only a few minutes. Most patients report pressure rather than sharp pain.

BENEFITS

With proper case selection and regular monitoring, Faricimab-svoa (Vabysmo) may provide:

1. Reduction of macular swelling
2. Stabilization or improvement of central vision
3. Longer possible intervals between injections in responsive patients
4. Evidence-based outcomes supported by large clinical trials

RISKS AND SAFETY INFORMATION

All intravitreal injections carry risk. Although uncommon, possible complications include infection, inflammation, retinal tear, retinal detachment, increased eye pressure, bleeding, or cataract progression. Temporary redness, irritation, floaters, or mild discomfort can also occur. Therefore, immediate follow-up is essential if severe pain, marked vision drop, or increasing redness develops.

This product description supports patient education but does not replace a full medical consultation, diagnostic workup, or individualized treatment plan.